Erasca reports early trial shows tumor shrinkage in 40% of pancreatic and 62% of lung cancer patients

Erasca announced that its experimental RAS-targeting oral drug, ERAS-0015, produced tumor reductions in a portion of patients with advanced pancreatic cancer and advanced non-small cell lung cancer.

In the trial, tumors shrank in 40% of the pancreatic cancer cohort and in 62% of the lung cancer cohort. The data were gathered from sites in the United States and China and are described as preliminary.

Erasca said the clinical benefit and tolerability appeared favorable compared with daraxonrasib, a similar RAS inhibitor from Revolution Medicines that recently reported a survival benefit in pancreatic cancer.

The company noted the results exceeded its internal expectations, but emphasized that further studies are needed to confirm efficacy and safety.